Method of Treating Colorectal Cancers Using a PKC Inhibitor
AssigneeUniversity of South Florida
InventorMildred Acevedo-Duncan
Life of this patent
Estimating the term…
Abstract
The subject invention pertains to methods of treating colorectal cancer by administering an atypical PKC inhibitor. The inhibitors of aPKC useful in the methods of the instant invention include ACPD, ICA-1, DNDA and ζ-Stat. Also provided are methods of measuring the susceptibility of colon cancer cells of a subject to inhibitors of aPKCs.
Claims19
A method of treating colon cancer in a patient in need thereof comprising administering a therapeutically effective amount of an atypical PKC inhibitor.
A method of measuring the susceptibility of colon cancer cells of a subject suffering from colon cancer to an aPKC inhibitor, the method comprising:
- obtaining a colon cell sample from a subject suffering from colon cancer, wherein the colon cell sample comprises cells suspected of being colon cancer cells and adjacent normal colon epithelial cells;
- measuring the expression of an atypical PKC in the cells of the colon cell sample that are suspected of being colon cancer cells;
- measuring the expression of an atypical PKC in the cells of the colon cell sample that are normal colon epithelial cells;
- in the case of a higher expression of at least one atypical PKC in the cells of the colon cancer sample compared to the normal colon epithelial cells, exposing a portion of the colon cancer cells of the colon cell sample to an inhibitor of an aPKC, while leaving another portion of the colon cancer cells of the colon cell sample untreated;
- measuring cell proliferation, expression and activation of aPKCs and markers of apoptosis and anti-apoptosis in treated and untreated cells;
- assigning susceptibility to the colon cancer cells of the subject if the proliferation, expression and activation of aPKCs and markers of apoptosis and anti-apoptosis are reduced in treated cells compared to untreated cells.
A method of reducing colon cancer cell proliferation comprising administering an effective amount of an atypical PKC inhibitor to colon cancer cells.
Dependencies are inferred from the claim text.